Novavax intends to use the $11 million in gross proceeds from this investment to pay a portion of its 4.75% senior convertible notes due in July 2009 and for a variety of other corporate purposes, including internal R&D programs, working capital and other general corporate purposes.
Novavax is a clinical-stage biotechnology company creating vaccines to address a range of infectious diseases using advanced proprietary virus-like-particle technology.